Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and hypofractionated radiotherapy for large brain metastases
NCT03778541Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in brain metastases (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Intracranial Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
temozolomide
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT03778541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778541.